Details of the Drug

General Information of Drug (ID: DMOAD2Y)

Drug Name
Dupilumab
Synonyms REGN-668; REGN-668); Anti-IL-4 monoclonal antibody (asthma/atopic dermatitis), sanofi-aventis; Anti-IL-4 receptor antibody (VelocImmune, allergy/immune disorder), Regeneron/sanofi-aventis
Indication
Disease Entry ICD 11 Status REF
Atopic dermatitis EA80 Approved [1]
Asthma CA23 Phase 3 [2]
Drug Type
Antibody
Sequence
>heavy chain
EVQLVESGGGLEQPGGSLRLSCAGSGFTFRDYAMTWVRQAPGKGLEWVSSISGSGGNTYY
ADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKDRLSITIRPRYYGLDVWGQGTT
VTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPA
VLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESKYGPPCPPCPAPEFL
GGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQ
FNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQPREPQVYTLPPSQ
EEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKS
RWQEGNVFSCSVMHEALHNHYTQKSLSLSLG
>light chain
DIVMTQSPLSLPVTPGEPASISCRSSQSLLYSIGYNYLDWYLQKSGQSPQLLIYLGSNRA
SGVPDRFSGSGSGTDFTLKISRVEAEDVGFYYCMQALQTPYTFGQGTKLEIKRTVAAPSV
FIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSL
SSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
ADMET Property
Absorption Cmax
The maximum plasma concentration (Cmax) of drug is 41.8 +/- 12.4 mg/L [3]
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 3-7 days [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 4.8 - 7 days [4]
Metabolism
The drug is metabolized via the hepatic [4]
Vd
The volume of distribution (Vd) of drug is 4.8 +/- 1.3 L [5]
Cross-matching ID
DrugBank ID
DB12159
TTD ID
D07FUP
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin 4 receptor alpha (IL4R) TTDWHC3 IL4RA_HUMAN Not Available [6]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

ICD Disease Classification 14 Disease of the skin
Disease Class ICD-11: EA90 Psoriasis
The Studied Tissue Skin
The Studied Disease Atopic dermatitis [ICD-11:EA90]
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Interleukin 4 receptor alpha (IL4R) DTT IL4R 1.48E-08 0.76 3.74
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Dupilumab (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Siponimod DM2R86O Major Additive immunosuppressive effects by the combination of Dupilumab and Siponimod. Multiple sclerosis [8A40] [7]
Ozanimod DMT6AM2 Major Additive immunosuppressive effects by the combination of Dupilumab and Ozanimod. Multiple sclerosis [8A40] [8]

References

1 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7574).
3 FDA Approved Drug Products: Dupixent (dupilumab) for subcutaneous injection
4 Dupixent, INN-dupilumab - European Medicines Agency - Europa EU
5 D'Ippolito D, Pisano M: Dupilumab (Dupixent): An Interleukin-4 Receptor Antagonist for Atopic Dermatitis. P T. 2018 Sep;43(9):532-535.
6 Dupilumab in persistent asthma with elevated eosinophil levels. N Engl J Med. 2013 Jun 27;368(26):2455-66.
7 Cerner Multum, Inc. "Australian Product Information.".
8 Cerner Multum, Inc. "UK Summary of Product Characteristics.".